search
Back to results

Satisfaction of Patients With Amyotrophic Lateral Sclerosis Regarding Home Assisted Teleconsultation (VNI_SLA)

Primary Purpose

ALS, Charcot Disease

Status
Not yet recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Teleconsultation assisted by a physiotherapist or nurse
Sponsored by
AGIR à Dom
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for ALS

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patient with a diagnosis of ALS coming for a follow-up consultation with their pneumologist Daily NIV compliance of more than 4 hours in the month prior to inclusion Living at home Patient with a natural caregiver Patient equipped with computer equipment adapted for teleconsultation (tablet, computer, telephone... with an internet connection) Patient able to read and understand the procedure, and able to express consent for the study protocol Patient, or his or her caregiver, able to sign the consent to participate by himself or herself Exclusion Criteria: Patient not available or wishing to change region within 3 months of inclusion Patient currently participating or having participated in the month prior to inclusion in another clinical interventional research study that may have an impact on the study, this impact is left to the discretion of the investigator Persons referred to in articles L1121-5 to L1121-8 of the French Public Health Code (corresponding to all protected persons) Pregnant women (for women of childbearing age and in the absence of reliable contraception, the β-HCG (human chorionic gonadotropin) assay will be performed), parturient women, breastfeeding women, persons deprived of their liberty by judicial or administrative decision, persons under legal protection

Sites / Locations

  • CHU Grenoble Alpes
  • CHU Montpellier

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Intervention

Control group

Arm Description

Patients who will be followed up by teleconsultation assisted by a physiotherapist or a nurse at home.

Patients not wishing to be followed up by teleconsultation but agreeing to participate in the study and the collection of questionnaires. They will follow up as usual in person (no teleconsultation).

Outcomes

Primary Outcome Measures

Satisfaction of ALS patients followed by teleconsultation at home
Evolution of the overall satisfaction score obtained from the Client Satisfaction Questionnaire CSQ-8, with 8 items, score 8-32. The higher the score, the more satisfied the patient is.

Secondary Outcome Measures

Evolution of the patient's physical functions
Change in ALS-FRS-R (Amyotrophic lateral sclerosis functional rating scale revised) questionnaire score, score 0-48. The higher the score, the better the patient's physical function.
Non-inferiority of ventilatory efficiency compared to conventional management
Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by S3-NIV (symptoms, sleep quality and side-effects related to the non-invasiv ventilation) questionnaire score 0-10. the higher the score, the fewer ALS-related symptoms the patient has.
Non-inferiority of ventilatory efficiency compared to conventional management
Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by mean nocturnal oxygen saturation (SpO2, %) measured by oximetry
Non-inferiority of ventilatory efficiency compared to conventional management
Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by time spent (in minutes) below 90% SpO2, measured by oximetry
Non-inferiority of ventilatory efficiency compared to conventional management
Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by mean PtCO2 (in mmHg), measured by capnography
Non-inferiority of ventilatory efficiency compared to conventional management
Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by time spent (in minutes) above 50 mmHg PtCO2 measured by capnography
Non-inferiority of ventilatory efficiency compared to conventional management
Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by the treatment compliance (average daily use) through telemonitoring of the data recorded by the CPAP machine.
Non-inferiority of ventilatory efficiency compared to conventional management
Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by the unintentional leakage through telemonitoring of the data recorded by the CPAP machine.
Non-inferiority of ventilatory efficiency compared to conventional management
Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by the residual Apnea-Hypopnea Index (AHI) through telemonitoring of the data recorded by the CPAP machine.
The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit
Comparison of the evolution of ventilation efficiency assessed from clinical parameters measured by S3-NIV (symptoms, sleep quality and side-effects related to the non-invasiv ventilation) questionnaire, score 0-10. the higher the score, the fewer ALS-related symptoms the patient has.
The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit
Comparison of the evolution of ventilation efficiency assessed from mean PtCO2 (in mmHg), measured by capnography
The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit
Comparison of the evolution of ventilation efficiency assessed from time spent (in minutes) below 90% SpO2, measured by oximetry
The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit
Comparison of the evolution of ventilation efficiency assessed from mean nocturnal oxygen saturation (SpO2,%) measured by oximetry
The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit
Comparison of the evolution of ventilation efficiency assessed from time spent (in minutes) above 50 mmHg PtCO2 measured by capnography
The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit
Comparison of the evolution of ventilation efficiency assessed by the treatment compliance (average daily use) through telemonitoring of the data recorded by the CPAP machine.
The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit
Comparison of the evolution of ventilation efficiency assessed by the unintentional leakage through telemonitoring of the data recorded by the CPAP machine.
The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit
Comparison of the evolution of ventilation efficiency assessed by the residual Apnea-Hypopnea Index (AHI) through telemonitoring of the data recorded by the CPAP machine.
Patient satisfaction with teleconsultation itself (use and patient/doctor interaction)
Evaluation of the score of the Visit Satisfaction Questionnaire (VSQ-VF) score 0-100. The higher the score, the more satisfied the patient is.
The evolution of satisfaction between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit
Comparison of the variation in the score of the visit satisfaction questionnaire, assessed by the VSQ-VF questionnaire, score 0-100. The higher the score, the more satisfied the patient is.
Physician satisfaction with teleconsultation
Evaluation made by Visual Analogue Scale (VAS) from 0 to 10 cm. The higher the score, the more satisfied the physician is.
Caregivers' satisfaction with the care of the relative
Change in caregiver satisfaction measured with client satisfaction questionnaire score (CSQ-8 modified) with 8 items, score 8-32. The higher the score, the more satisfied the caregivers' is.
The feasibility of home teleconsultation for ALS patients
Number of failed teleconsultations requiring rescheduling
Retention of follow-up modality
Number of patients who changed follow-up modality, assessed by the number of face-to-face follow-up

Full Information

First Posted
October 27, 2022
Last Updated
November 16, 2022
Sponsor
AGIR à Dom
search

1. Study Identification

Unique Protocol Identification Number
NCT05621213
Brief Title
Satisfaction of Patients With Amyotrophic Lateral Sclerosis Regarding Home Assisted Teleconsultation
Acronym
VNI_SLA
Official Title
Satisfaction of Patients With Amyotrophic Lateral Sclerosis Under Non-invasive Ventilation Regarding Home Assisted Teleconsultation
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
November 30, 2022 (Anticipated)
Primary Completion Date
May 31, 2023 (Anticipated)
Study Completion Date
August 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AGIR à Dom

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Satisfaction of patients with amyotrophic lateral sclerosis under non-invasive ventilation regarding home assisted teleconsultation
Detailed Description
Amyotrophic Lateral Sclerosis (ALS) is a progressive and rapidly progressing neurodegenerative disease. Depending on the degree of muscle damage, patients may suffer from reduced mobility, difficulty swallowing, speech difficulties and finally respiratory weakness. Death occurs within an average of 2-3 years and is usually due to respiratory failure. Currently there is no cure for ALS, so palliative care and symptomatic treatments are essential for the management of these patients. The gold standard treatment for respiratory impairment is non-invasive ventilation (NIV). The aim of this mask ventilation is to improve gas exchange by compensating for the weakness of the respiratory muscles. The progressive nature of ALS requires regular assessment of the patient's clinical condition and evaluation of NIV parameters. Regular medical appointments are therefore essential to ensure optimal ventilation and close surveillance of the patient. A day hospitalization or a consultation is organized every 3 or 4 months. These visits can cause significant fatigue, not only because of the difficulty patients have to move around but also because of the time spent waiting in hospital. ALS is characterised by its severity and it requires our society to think about and implement new ways of managing the disease. Thus, e-health innovations could be an interesting potential in the remote follow-up of these patients, to reduce the burden of hospital consultations. The hypothesis is that the patient will be more satisfied with a home assisted teleconsultation follow-up, while keeping the same quality of non-invasive nocturnal ventilatory assistance.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
ALS, Charcot Disease

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Patient assigned to the interventional group or to the control group if they do not wish to be followed up by teleconsultation
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention
Arm Type
Experimental
Arm Description
Patients who will be followed up by teleconsultation assisted by a physiotherapist or a nurse at home.
Arm Title
Control group
Arm Type
No Intervention
Arm Description
Patients not wishing to be followed up by teleconsultation but agreeing to participate in the study and the collection of questionnaires. They will follow up as usual in person (no teleconsultation).
Intervention Type
Other
Intervention Name(s)
Teleconsultation assisted by a physiotherapist or nurse
Intervention Description
A home health care provider (with expertise in NIV) will be asked to attend the 2 home teleconsultation sessions. This assistance will make it possible to help, if necessary, the patient to settle in and connect, collect the elements necessary for the doctor's consultation and adjust, if necessary, the NIV settings. He will also be responsible for administering the questionnaires to the patient as well as to his family caregiver.
Primary Outcome Measure Information:
Title
Satisfaction of ALS patients followed by teleconsultation at home
Description
Evolution of the overall satisfaction score obtained from the Client Satisfaction Questionnaire CSQ-8, with 8 items, score 8-32. The higher the score, the more satisfied the patient is.
Time Frame
Between the initial visit and the 3-month visit
Secondary Outcome Measure Information:
Title
Evolution of the patient's physical functions
Description
Change in ALS-FRS-R (Amyotrophic lateral sclerosis functional rating scale revised) questionnaire score, score 0-48. The higher the score, the better the patient's physical function.
Time Frame
Between the initial visit, the 3-month visit, and the 6-months visit
Title
Non-inferiority of ventilatory efficiency compared to conventional management
Description
Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by S3-NIV (symptoms, sleep quality and side-effects related to the non-invasiv ventilation) questionnaire score 0-10. the higher the score, the fewer ALS-related symptoms the patient has.
Time Frame
Between the initial visit, the 3-month visit, and the 6-months visit
Title
Non-inferiority of ventilatory efficiency compared to conventional management
Description
Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by mean nocturnal oxygen saturation (SpO2, %) measured by oximetry
Time Frame
Between the initial visit, the 3-month visit, and the 6-months visit
Title
Non-inferiority of ventilatory efficiency compared to conventional management
Description
Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by time spent (in minutes) below 90% SpO2, measured by oximetry
Time Frame
Between the initial visit, the 3-month visit, and the 6-months visit
Title
Non-inferiority of ventilatory efficiency compared to conventional management
Description
Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by mean PtCO2 (in mmHg), measured by capnography
Time Frame
Between the initial visit, the 3-month visit, and the 6-months visit
Title
Non-inferiority of ventilatory efficiency compared to conventional management
Description
Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by time spent (in minutes) above 50 mmHg PtCO2 measured by capnography
Time Frame
Between the initial visit, the 3-month visit, and the 6-months visit
Title
Non-inferiority of ventilatory efficiency compared to conventional management
Description
Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by the treatment compliance (average daily use) through telemonitoring of the data recorded by the CPAP machine.
Time Frame
Between the initial visit, the 3-month visit, and the 6-months visit
Title
Non-inferiority of ventilatory efficiency compared to conventional management
Description
Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by the unintentional leakage through telemonitoring of the data recorded by the CPAP machine.
Time Frame
Between the initial visit, the 3-month visit, and the 6-months visit
Title
Non-inferiority of ventilatory efficiency compared to conventional management
Description
Non-inferiority of efficiency will be assessed in a blinded manner by two third party experts in ventilation. This ventilatory efficiency will be assessed by the residual Apnea-Hypopnea Index (AHI) through telemonitoring of the data recorded by the CPAP machine.
Time Frame
Between the initial visit, the 3-month visit, and the 6-months visit
Title
The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit
Description
Comparison of the evolution of ventilation efficiency assessed from clinical parameters measured by S3-NIV (symptoms, sleep quality and side-effects related to the non-invasiv ventilation) questionnaire, score 0-10. the higher the score, the fewer ALS-related symptoms the patient has.
Time Frame
Between the initial visit, the 3-month visit, and the 6-months visit
Title
The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit
Description
Comparison of the evolution of ventilation efficiency assessed from mean PtCO2 (in mmHg), measured by capnography
Time Frame
Between the initial visit, the 3-month visit, and the 6-months visit
Title
The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit
Description
Comparison of the evolution of ventilation efficiency assessed from time spent (in minutes) below 90% SpO2, measured by oximetry
Time Frame
Between the initial visit, the 3-month visit, and the 6-months visit
Title
The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit
Description
Comparison of the evolution of ventilation efficiency assessed from mean nocturnal oxygen saturation (SpO2,%) measured by oximetry
Time Frame
Between the initial visit, the 3-month visit, and the 6-months visit
Title
The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit
Description
Comparison of the evolution of ventilation efficiency assessed from time spent (in minutes) above 50 mmHg PtCO2 measured by capnography
Time Frame
Between the initial visit, the 3-month visit, and the 6-months visit
Title
The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit
Description
Comparison of the evolution of ventilation efficiency assessed by the treatment compliance (average daily use) through telemonitoring of the data recorded by the CPAP machine.
Time Frame
Between the initial visit, the 3-month visit, and the 6-months visit
Title
The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit
Description
Comparison of the evolution of ventilation efficiency assessed by the unintentional leakage through telemonitoring of the data recorded by the CPAP machine.
Time Frame
Between the initial visit, the 3-month visit, and the 6-months visit
Title
The evolution of the efficiency of ventilation between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit
Description
Comparison of the evolution of ventilation efficiency assessed by the residual Apnea-Hypopnea Index (AHI) through telemonitoring of the data recorded by the CPAP machine.
Time Frame
Between the initial visit, the 3-month visit, and the 6-months visit
Title
Patient satisfaction with teleconsultation itself (use and patient/doctor interaction)
Description
Evaluation of the score of the Visit Satisfaction Questionnaire (VSQ-VF) score 0-100. The higher the score, the more satisfied the patient is.
Time Frame
After each teleconsultation (3-month visit and 6-month visit)
Title
The evolution of satisfaction between patients who have completed the teleconsultation follow-up visit and those who have completed the face-to-face follow-up visit
Description
Comparison of the variation in the score of the visit satisfaction questionnaire, assessed by the VSQ-VF questionnaire, score 0-100. The higher the score, the more satisfied the patient is.
Time Frame
Between the 3-month visit, and the 6-months visit
Title
Physician satisfaction with teleconsultation
Description
Evaluation made by Visual Analogue Scale (VAS) from 0 to 10 cm. The higher the score, the more satisfied the physician is.
Time Frame
After each teleconsultation (3-month visit and 6-month visit)
Title
Caregivers' satisfaction with the care of the relative
Description
Change in caregiver satisfaction measured with client satisfaction questionnaire score (CSQ-8 modified) with 8 items, score 8-32. The higher the score, the more satisfied the caregivers' is.
Time Frame
Between the initial visit, the 3-month visit, and the 6-months visit
Title
The feasibility of home teleconsultation for ALS patients
Description
Number of failed teleconsultations requiring rescheduling
Time Frame
Between the initial visit, the 3-month visit, and the 6-months visit
Title
Retention of follow-up modality
Description
Number of patients who changed follow-up modality, assessed by the number of face-to-face follow-up
Time Frame
At 6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient with a diagnosis of ALS coming for a follow-up consultation with their pneumologist Daily NIV compliance of more than 4 hours in the month prior to inclusion Living at home Patient with a natural caregiver Patient equipped with computer equipment adapted for teleconsultation (tablet, computer, telephone... with an internet connection) Patient able to read and understand the procedure, and able to express consent for the study protocol Patient, or his or her caregiver, able to sign the consent to participate by himself or herself Exclusion Criteria: Patient not available or wishing to change region within 3 months of inclusion Patient currently participating or having participated in the month prior to inclusion in another clinical interventional research study that may have an impact on the study, this impact is left to the discretion of the investigator Persons referred to in articles L1121-5 to L1121-8 of the French Public Health Code (corresponding to all protected persons) Pregnant women (for women of childbearing age and in the absence of reliable contraception, the β-HCG (human chorionic gonadotropin) assay will be performed), parturient women, breastfeeding women, persons deprived of their liberty by judicial or administrative decision, persons under legal protection
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Céline Barra
Phone
0750543238
Ext
+33
Email
c.barra@agiradom.com
First Name & Middle Initial & Last Name or Official Title & Degree
Jean-Christian Borel, PhD
Phone
0762707821
Ext
+33
Email
j.borel@agiradom.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christel Saint-Raymond, PhD
Organizational Affiliation
CHU Grenoble Alpes
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU Grenoble Alpes
City
Grenoble
ZIP/Postal Code
38043
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christel Saint-Raymond, PhD
Email
csaint-raymond@chu-grenoble.fr
First Name & Middle Initial & Last Name & Degree
Christel Saint-Raymond, PhD
Facility Name
CHU Montpellier
City
Montpellier
ZIP/Postal Code
34295
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
François Bughin, PhD
Phone
0499536218
Ext
+33
Email
f-bughin@chu-montpellier.fr
First Name & Middle Initial & Last Name & Degree
Bronia Ayoub
Email
b-ayoub@chu-montpellier.fr
First Name & Middle Initial & Last Name & Degree
François Bughin, PhD

12. IPD Sharing Statement

Learn more about this trial

Satisfaction of Patients With Amyotrophic Lateral Sclerosis Regarding Home Assisted Teleconsultation

We'll reach out to this number within 24 hrs